Insulet Corporation Stock News

Lots of investors fear the advent of weight loss drugs could take a toll on insulin pump maker Insulet, by curbing diabetes. Cable television company Charter Communications is bumping into a new headw

In the fourth quarter, Insulet (PODD) achieves the milestone of 425,000 estimated active global customers using Omnipod products.

Insulet (PODD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising e

Although the revenue and EPS for Insulet (PODD) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Stre

Insulet (PODD) came out with quarterly earnings of $1.40 per share, beating the Zacks Consensus Estimate of $0.67 per share. This compares to earnings of $0.55 per share a year ago.

The huge success of Omnipod 5 boosts investors' confidence in Insulet (PODD).

Insulet's (PODD) tubeless automated insulin delivery system's CE mark approval with multiple CGM sensor brands is likely to serve a wider patient pool.

Insulet (PODD) could produce exceptional returns because of its solid growth attributes.

Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.

Sector components forecast to show the biggest earnings year-over-year earnings improvement include Humana Inc. NYSE: HUM, Elevance Health Inc. NYSE: ELV, Incyte Corp. NASDAQ: INCY, Insulet Corp.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced

Each earnings reporting season, you can count on a flurry of articles with headlines saying companies “beat” consensus estimates for quarterly profits. But that “success” alone means nothing.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Insulet (PODD) is well positioned to outperform the market, as it exhibits above-average growth in financials.